Acute Leukemias IV

Prognostic Factors and Treatment Strategies

  • T. Büchner
  • W. Hiddemann
  • B. Wörmann
  • G. Schellong
  • J. Ritter

Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Table of contents

  1. Front Matter
    Pages I-XXXVI
  2. The Treatment of Acute Leukemia: Observations by a Marrow Transplanter

  3. Leukemia Cell Biology

    1. Front Matter
      Pages 7-7
    2. A. Biondi, C. R. Bartram, A. Rambaldi, V. Rossi, A. Luciano, M. Cavana et al.
      Pages 9-14
    3. J. Pedersen-Bjergaard, P. Philip, S. O. Larsen, M. Andersson, G. Daugaard, J. Ersbøll et al.
      Pages 15-23
    4. W. D. Ludwig, J. Harbott, H. Rieder, C. R. Bartram, J. Maurer, R. Becher et al.
      Pages 24-32
    5. M. Bentz, H. Döhner, M. Schröder, S. Pohl, P. Lichter
      Pages 38-42
    6. O. M. Koch, M. Volkenandt, E. Göker, J. Buer, R. Wienecke, D. Banerjee et al.
      Pages 47-50
    7. A. Beishuizen, M-A. J. Verhoeven, K. Hählen, E. R. van Wering, J. J. M. van Dongen
      Pages 51-58
    8. F. Griesinger, H. Elfers, B. Wörmann, J. Ritter, T. Büchner, J. van de Loo et al.
      Pages 59-64
    9. A. Borkhardt, R. Repp, J. Harbott, C. Keller, F. Lampert
      Pages 71-74
    10. C.-M. Wendtner, N. Sacchi, T. Büchner, W. Hiddemann, J. van de Loo, B. Wörmann
      Pages 75-80
    11. C. Preudhomme, I. Quiquandon, P. Jonveaux, J. L. Laï, M. Vanrumbeke, M. H. Loucheux-Lefebvre et al.
      Pages 81-84
    12. C. Schardt, C. Schardt, H. G. Drexler, A. Ganser, D. Hoelzer
      Pages 85-89
    13. K. Fenchel, L. Bergmann, B. Jahn, P. S. Mitrou
      Pages 90-95
    14. P. Kogner, A. Ericsson, G. Barbany, H. Persson, E. Theodorsson, O. Björk
      Pages 102-105
    15. A. Yu. Zaritskey, O. V. Strijak, L. S. Zubarovskaya, K. V. Efimov, B. V. Afanasiev
      Pages 106-109
    16. H.-D. Kleine, U. Wagner, E. Lux, G. Döring, H. Poliwoda, M. Freund
      Pages 110-115
    17. D. Montagna, M. Aricò, E. Montini, F. De Benedetti, A. Martini, R. Maccario
      Pages 116-120
  4. Novel Therapeutic Approaches

    1. Front Matter
      Pages 127-127
    2. V. Gandhi, M. J. Keating, E. Estey, W. Plunkett
      Pages 133-137
    3. T. Büchner, W. Hiddemann, R. Rottmann, B. Wörmann, M. Zühlsdorf, G. Maschmeyer et al.
      Pages 138-141
  5. Etoposide Update of Clinical Experiences

  6. Hematopoietic Growth Factors: New Aspects for Leukemia Treatment

    1. Front Matter
      Pages 179-179
    2. M. Zühlsdorf, S. Weisspfennig, C. Busemann, C. Ameling, B. Wörmann, W. Hiddemann et al.
      Pages 181-184
    3. A. Ganser, O. G. Ottmann, D. Hoelzer
      Pages 185-200
    4. J. M. Vose, E. C. Reed, P. J. Bierman, J. O. Armitage
      Pages 201-204
  7. Mitoxantrone: Impact on the Treatment of Leukemias and Lymphomas

    1. Front Matter
      Pages 205-205
    2. M. Björkholm, The Leukemia Group of Middle Sweden (LGMS)
      Pages 216-220
    3. E. Schleyer, A. Kamischke, C. C. Kaufmann, M. Unterhalt, W. Hiddemann
      Pages 221-230
    4. Z. A. Arlin, P. Cook, T. Ahmed, A. Mittelman, C. Puccio, H. G. Chun et al.
      Pages 231-234
    5. J. M. Rowe, J. W. Andersen, J. J. Mazza, J. D. Hines, J. M. Bennett, P. A. Cassileth et al.
      Pages 235-238
  8. Pharmacokinetics

    1. Front Matter
      Pages 239-239
    2. K. Schumacher, E. Ladda, K. Bühl, A. Weimer, C. Eser, U. Traugott et al.
      Pages 245-249
    3. V. Runde, C. Aul, A. Höller, W. Schneider
      Pages 250-253

About these proceedings


The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans­ plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias.


bone marrow cancer cell chemotherapy classification clinical trial cytogenetics growth immunotherapy interferon leukemia lymphoma oncology steroids transplantation

Editors and affiliations

  • T. Büchner
    • 1
  • W. Hiddemann
    • 3
  • B. Wörmann
    • 3
  • G. Schellong
    • 2
  • J. Ritter
    • 2
  1. 1.Department of Internal MedicineGermany
  2. 2.Department of PediatricsUniversity of MünsterMünsterGermany
  3. 3.Department of Internal MedicineUniversity of GöttingenGöttingenGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-78352-4
  • Online ISBN 978-3-642-78350-0
  • Series Print ISSN 0440-0607
  • Buy this book on publisher's site